| Description |
1 online resource (xi, 263 pages, 2 unnumbered pages of plates) : illustrations (some color) |
| Series |
Biotechnology : pharmaceutical aspects ; v. 8 |
|
Biotechnology (Arlington, Va.) ; v. 8.
|
| Contents |
Front Matter; Immune Reactions Towards Biopharmaceuticals -- a General, Mechanistic Overview; Clinical Aspects of Immunogenicity to Biopharmaceuticals; Assessment of Unwanted Immunogenicity; Models for Prediction of Immunogenicity; Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars; Case Study: Immunogenicity of rhEPO; Case Study: Immunogenicity of Interferon-Beta; Case Study: Immunogenicity of Insulin; Case Study: Immunogenicity of Factor VIII; Case Study: Immunogenicity of Natalizumab; Case Study: Immunogenicity of Anti-TNF Antibodies |
| Summary |
A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho??'s blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Biopharmaceutics -- Immunology
|
|
Immunological tolerance.
|
|
Pharmaceutical biotechnology.
|
|
Immune Tolerance
|
|
MEDICAL -- Immunology.
|
|
Pharmaceutical biotechnology.
|
|
Biopharmaceutics -- Immunology.
|
|
Immunological tolerance.
|
|
Biomédecine.
|
|
Sciences de la vie.
|
|
Immunological tolerance
|
|
Pharmaceutical biotechnology
|
| Form |
Electronic book
|
| Author |
Weert, Marco van de, 1973-
|
|
Møller, Eva Horn
|
| ISBN |
9780387758411 |
|
0387758410 |
|
0387758402 |
|
9780387758404 |
|
